Companies covered: Spyre Therapeutics, Inc. (NASDAQ:SYRE), Kiniksa Pharmaceuticals International PLC (NASDAQ:KNSA), BridgeBio Oncology Therapeutics, Inc. (NASDAQ:BBOT), ORIC Pharmaceuticals Inc. (NASDAQ:ORIC), Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), Merck & Company, Inc. (NYSE:MRK), Johnson & Johnson (NYSE:JNJ), Novo Nordisk A/S (NYSE:NVO), Revolution Medicines, Inc. (NASDAQ:RVMD), Omeros Corporation (NASDAQ:OMER), Marker Therapeutics, Inc. (NASDAQ:MRKR), Turn Therapeutics, Inc. (NASDAQ:TTRX), AbbVie Inc. (NYSE:ABBV), Amgen Inc. (NASDAQ:AMGN), Insmed, Inc. (NASDAQ:INSM), Argenx SE (ADR) (NASDAQ:ARGX), Eli Lilly and Company (NYSE:LLY), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), Bristol-Myers Squibb Company (NYSE:BMY), Pfizer, Inc. (NYSE:PFE), Syndax Pharmaceuticals Inc (NASDAQ:SNDX), Kura Oncology, Inc. (NASDAQ:KURA), Cullinan Therapeutics Inc. (NASDAQ:CGEM), Genmab A/S - ADR (NASDAQ:GMAB), Autolus Therapeutics PLC (NASDAQ:AUTL), Xencor, Inc. (NASDAQ:XNCR), NewAmsterdam Pharma Company NV (NASDAQ:NAMS), BioVie Inc. (NASDAQ:BIVI), CytoMed Therapeutics Ltd. (NASDAQ:GDTC), Enlivex Therapeutics Ltd. (NASDAQ:ENLV), Mesoblast Limited (NASDAQ:MESO), Neuren Pharmaceuticals Ltd. (OTCMKTS:NURPF), Niagen Bioscience Inc. (NASDAQ:NAGE), PDS Biotechnology Corporation (NASDAQ:PDSB), Vaxart (OTCMKTS:VXRT)
